The US Food and Drug Administration has approved an oral version of Novo Nordisk’s popular weight loss drug Wegovy, marking a significant expansion in obesity treatment options. The approval allows Wegovy to be taken as a daily pill instead of an injection, making it the first GLP-1 based
